[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536689":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":49,"collaborators":19,"id":51,"slug":19,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":19,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":19,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":19,"overallStatus":35,"whyStopped":19,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Thalidomide","EXPERIMENTAL","Oral Thalidomide",[13],"Drug: Thalidomide",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Thalidomide 50 - 200 mg once at nightime",[9],null,[21],{"name":22,"affiliation":5,"role":23},"fengzeng jian","STUDY_CHAIR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+861083198899","jianfengzeng@xwh.ccmu.edu.cn",{"name":30,"role":26,"phone":27,"phoneExt":19,"email":31},"chenghua yuan","yuanchenghua@ccmu.edu.cn",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Fengzeng Jian","RECRUITING","Beijing","Beijing City","100032","China",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":48,"role":26,"phone":19,"phoneExt":19,"email":28},"fengzeng jian, md",{"type":50,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100536689",false,"NCT06268093","The Therapeutic Effect of Thalidomide in Syringomyelia","The Effect of Thalidomide in Refractory Syringomyelia（RS）: a Phase II Clinical Trial","Inclusion Criteria:\n\n* Contraindication to duraplasty and shunting treatment due to history or high risk of severe adverse effects,\n* or non-effective response to duraplasty and shunting treatment in 12 months prior to study entry.\n* Estimated life expectancy must be greater than 12 months.\n* Routine laboratory studies: bilirubin \\\u003C\u002F=1.0 \\* upper limits of normal (ULN); aspartate aminotransferase (AST or SGOT) or alanine aminotransferase (ALT)\\\u003C 1.0 \\* ULN; creatinine \\\u003C1.0 \\* ULN; white-cell count \\>\u002F= 4,000 per cubic millimeter; neutrophils count \\>\u002F=1500 per cubic millimeter platelets \\>\u002F= 100,000 per cubic millimeter; Hb \\>\u002F=110 gram per millilitres; PT, APTT, INR in a normal range.\n* Ability to understand and willingness to sign a written informed consent document, or constant caregivers who well understand and willingness to sign a written informed consent document.\n* Must be able to swallow tablets\n\nExclusion Criteria:\n\n* Evidence of tumor metastasis, recurrence, or invasion;\n* History of psychiatric diseases ;\n* History of seizures;\n* History of arteriosclerotic cardiovascular diseases (ASCVD), e.g. stroke, myocardial infaction, unstable angina, within 6 months;\n* New York Heart Association Grade II or greater congestive heart failure;\n* Serious and inadequately controlled cardiac arrhythmia;\n* Significant vascular disease, e.g. moderate or severe carotid stenosis, aortic aneurysm, history of aortic dissection;\n* Severe infection;\n* History of allergy to relevant drugs;\n* Pregnancy, lactation, or fertility program in the following 12 months;\n* History or current diagnosis of peripheral nerve disease;\n* Abnormal in liver and renal function;\n* Active tuberculosis;\n* Transplanted organs;\n* Human immunodeficiency virus;\n* Participation in other experimental studies.","ALL","18 Years","80 Years",{"count":61,"type":62},30,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","Purpose: This phase II clinical trial aims to evaluate the indications, therapeutic effects and side effects of thalidomide in refractory syringomyelia.\n\nPrimary outcome measure: The primary endpoint is the change of ASIA at week 12. The clinical efficacy is defined as ASIA increase ≥ 1 at week 12, as compared with that before thalidomide usage.",[68,9],"Syringomyelia","2024-02-19",{"date":71,"type":72},"2024-02-20","ACTUAL",{"date":74,"type":62},"2024-02",{"date":76,"type":62},"2028-02",{"name":5,"class":6},1]